Loomis, Sayles & Company
MDCO

Loomis, Sayles & Company’s Medicines Co MDCO Stock Holding History

Loomis, Sayles & Company’s Portfolio MDCO Stock Details MDCO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-367,190
Closed -$12.5M – 1067
2016
Q4 		$12.5M Buy
367,190
+20,644
+6% +$732K 0.03% 385
2016
Q3 		$13.1M Buy
346,546
+346,486
+577,477% +$13.1M 0.03% 376
2016
Q2 		$2K Hold
60
– – ﹤0.01% 962
2016
Q1 		$2K Buy
+60
New +$1.96K ﹤0.01% 1003
2014
Q2 		– Sell
-512,429
Closed -$14.6M – 792
2014
Q1 		$14.6M Buy
512,429
+199,734
+64% +$6.61M 0.04% 439
2013
Q4 		$12.1M Buy
+312,695
New +$11.2M 0.04% 467

Other funds holding MDCO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
CM
Corvex Management New York $2.52B AUM 25.53% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Loomis, Sayles & Company's MDCO Position: Q1 2017 in Review

Loomis, Sayles & Company sold out of Medicines Co (MDCO) in Q1 2017, closing a stake of 367,190 shares — an estimated $12.5M sold.

Loomis, Sayles & Company first reported a position in MDCO in Q4 2013 and held it in 6 quarters. The position peaked at $14.6M in Q1 2014. 220 funds tracked by Wall St. Rank hold MDCO as of Q1 2017.

  • Loomis, Sayles & Company reported no remaining Medicines Co position as of Q1 2017 after selling out during the quarter.
  • Loomis, Sayles & Company sold 367,190 Medicines Co shares in Q1 2017, an estimated $12.5M.
  • Loomis, Sayles & Company first reported a position in Medicines Co in Q4 2013 and held it in 6 quarters.
  • Loomis, Sayles & Company's Medicines Co position peaked at $14.6M in Q1 2014.
  • 220 funds tracked by Wall St. Rank held Medicines Co as of Q1 2017.

Based on Loomis, Sayles & Company's 13F filing for Q1 2017, filed 12 May 2017.